MHRA authorises new treatment for rare lung cancer
A “potential best-in-class treatment” for adults with KRASG12C-mutated non-small cell lung cancer (NSCLC) has been authorised in the UK.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
